Pfizer’s abrocitinib scores another phase III win in atopic dermatitis

12th November 2020 Uncategorised 0

JADE REGIMEN study investigated JAK1 inhibitor in moderate to severe atopic dermatitis

More: Pfizer’s abrocitinib scores another phase III win in atopic dermatitis
Source: News